BACKGROUND: An optimal blood pressure (BP) range to mitigate morbidity and mortality on left ventricular assist device (LVAD) support has not been clearly defined. METHODS: Average Doppler opening pressure, mean arterial pressure (MAP), and/or systolic blood pressure (SBP) were calculated in operative survivors (n = 16,155) of LVAD support in the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS). BP distributions were used to group patients into low (BP <25th percentile), normal (25-75th percentile), high (75th-95th percentile), and very high (>95th percentile). Associations between BP and adverse events were evaluated using Cox regression (hazard ratio[HR], 95% confidence interval). RESULTS: The median (25th, 75th) MAP, Doppler, and SBP (mm Hg) during continuous flow LVAD support were 84 (77, 90), 85 (80, 92), and 99 (90, 107) mm Hg, respectively. BP had a bimodal risk association with survival. At 3 years, survival was 58% ± 1.8% in those with low MAP (≤75 mm Hg) vs 70% ± 0.9%, 71% ± 1.5%, and 63% ± 3.0% in the those with normal, high, or very high average MAP, respectively. Patients with chronically low MAP (≤75 mm Hg), Doppler (≤80 mm Hg), and SBP (<90 mm Hg) had 35%-42% higher adjusted hazards of death than patients with normal or high BP (p ≤ 0.0001). Patients with MAP >100 mm Hg, Doppler ≥105 mm Hg, and SBP ≥120 mm Hg had 17%-20% higher adjusted hazards of death than those with normal pressures (p < 0.05). In patients on axial flow LVADs, elevated SBP (HR 1.08 [95% confidence interval, 1.04-1.13] per 10 mm Hg increase) but not MAP correlated with increased incident of stroke. CONCLUSIONS: In INTERMACS, BP extremes during LVAD support increase the risk for adverse events, supporting a MAP goal >75 mm Hg and <90 mm Hg. Hypotension conferred the highest risk for mortality. Excessive BP control should be avoided, and Doppler opening pressure should not be assumed to represent MAP in all patients.
BACKGROUND: An optimal blood pressure (BP) range to mitigate morbidity and mortality on left ventricular assist device (LVAD) support has not been clearly defined. METHODS: Average Doppler opening pressure, mean arterial pressure (MAP), and/or systolic blood pressure (SBP) were calculated in operative survivors (n = 16,155) of LVAD support in the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS). BP distributions were used to group patients into low (BP <25th percentile), normal (25-75th percentile), high (75th-95th percentile), and very high (>95th percentile). Associations between BP and adverse events were evaluated using Cox regression (hazard ratio[HR], 95% confidence interval). RESULTS: The median (25th, 75th) MAP, Doppler, and SBP (mm Hg) during continuous flow LVAD support were 84 (77, 90), 85 (80, 92), and 99 (90, 107) mm Hg, respectively. BP had a bimodal risk association with survival. At 3 years, survival was 58% ± 1.8% in those with low MAP (≤75 mm Hg) vs 70% ± 0.9%, 71% ± 1.5%, and 63% ± 3.0% in the those with normal, high, or very high average MAP, respectively. Patients with chronically low MAP (≤75 mm Hg), Doppler (≤80 mm Hg), and SBP (<90 mm Hg) had 35%-42% higher adjusted hazards of death than patients with normal or high BP (p ≤ 0.0001). Patients with MAP >100 mm Hg, Doppler ≥105 mm Hg, and SBP ≥120 mm Hg had 17%-20% higher adjusted hazards of death than those with normal pressures (p < 0.05). In patients on axial flow LVADs, elevated SBP (HR 1.08 [95% confidence interval, 1.04-1.13] per 10 mm Hg increase) but not MAP correlated with increased incident of stroke. CONCLUSIONS: In INTERMACS, BP extremes during LVAD support increase the risk for adverse events, supporting a MAP goal >75 mm Hg and <90 mm Hg. Hypotension conferred the highest risk for mortality. Excessive BP control should be avoided, and Doppler opening pressure should not be assumed to represent MAP in all patients.
Authors: Joseph G Rogers; Francis D Pagani; Antone J Tatooles; Geetha Bhat; Mark S Slaughter; Emma J Birks; Steven W Boyce; Samer S Najjar; Valluvan Jeevanandam; Allen S Anderson; Igor D Gregoric; Hari Mallidi; Katrin Leadley; Keith D Aaronson; O H Frazier; Carmelo A Milano Journal: N Engl J Med Date: 2017-02-02 Impact factor: 91.245
Authors: Samer S Najjar; Mark S Slaughter; Francis D Pagani; Randall C Starling; Edwin C McGee; Peter Eckman; Antone J Tatooles; Nader Moazami; Robert L Kormos; David R Hathaway; Kevin B Najarian; Geetha Bhat; Keith D Aaronson; Steven W Boyce Journal: J Heart Lung Transplant Date: 2013-12-12 Impact factor: 10.247
Authors: Alberto Pinsino; Francesco Castagna; Amelia M Zuver; Eugene A Royzman; Mojdeh Nasiri; Eric J Stöhr; Barbara Cagliostro; Barry McDonnell; John R Cockcroft; A Reshad Garan; Veli K Topkara; P Christian Schulze; Koji Takeda; Hiroo Takayama; Yoshifumi Naka; Ryan T Demmer; Joshua Z Willey; Melana Yuzefpolskaya; Paolo C Colombo Journal: J Heart Lung Transplant Date: 2018-11-15 Impact factor: 10.247
Authors: Simon Maltais; Ahmet Kilic; Sriram Nathan; Mary Keebler; Sitaramesh Emani; John Ransom; Jason N Katz; Brett Sheridan; Andreas Brieke; Gregory Egnaczyk; John W Entwistle; Robert Adamson; John Stulak; Nir Uriel; John B O'Connell; David J Farrar; Kartik S Sundareswaran; Igor Gregoric Journal: J Heart Lung Transplant Date: 2016-11-16 Impact factor: 10.247
Authors: Michael E Nassif; Anjan Tibrewala; David S Raymer; Adam Andruska; Eric Novak; Justin M Vader; Akinobu Itoh; Scott C Silvestry; Gregory A Ewald; Shane J LaRue Journal: J Heart Lung Transplant Date: 2014-10-23 Impact factor: 10.247
Authors: Gregg M Lanier; Khristine Orlanes; Yacki Hayashi; Jennifer Murphy; Margaret Flannery; Rosie Te-Frey; Nir Uriel; Melana Yuzefpolskaya; Donna M Mancini; Yoshifumi Naka; Hiroo Takayama; Ulrich P Jorde; Ryan T Demmer; Paolo C Colombo Journal: Circ Heart Fail Date: 2013-06-27 Impact factor: 8.790
Authors: Carmelo A Milano; Joseph G Rogers; Antone J Tatooles; Geetha Bhat; Mark S Slaughter; Emma J Birks; Nahush A Mokadam; Claudius Mahr; Jeffrey S Miller; David W Markham; Valluvan Jeevanandam; Nir Uriel; Keith D Aaronson; Thomas A Vassiliades; Francis D Pagani Journal: JACC Heart Fail Date: 2018-07-11 Impact factor: 12.035
Authors: Jeffrey J Teuteberg; Mark S Slaughter; Joseph G Rogers; Edwin C McGee; Francis D Pagani; Robert Gordon; Eduardo Rame; Michael Acker; Robert L Kormos; Christopher Salerno; Thomas P Schleeter; Daniel J Goldstein; Julia Shin; Randall C Starling; Thomas Wozniak; Adnan S Malik; Scott Silvestry; Gregory A Ewald; Ulrich P Jorde; Yoshifumi Naka; Emma Birks; Kevin B Najarian; David R Hathaway; Keith D Aaronson Journal: JACC Heart Fail Date: 2015-10 Impact factor: 12.035
Authors: Davor Milicic; Binyamin Ben Avraham; Ovidiu Chioncel; Yaron D Barac; Eva Goncalvesova; Avishai Grupper; Johann Altenberger; Maria Frigeiro; Arsen Ristic; Nicolaas De Jonge; Steven Tsui; Jacob Lavee; Giuseppe Rosano; Marisa Generosa Crespo-Leiro; Andrew J S Coats; Petar Seferovic; Frank Ruschitzka; Marco Metra; Stefan Anker; Gerasimos Filippatos; Stamatis Adamopoulos; Miriam Abuhazira; Jeremy Elliston; Israel Gotsman; Righab Hamdan; Yoav Hammer; Tal Hasin; Lorrena Hill; Osnat Itzhaki Ben Zadok; Wilfried Mullens; Sanemn Nalbantgil; Massimo Francesco Piepoli; Piotr Ponikowski; Luciano Potena; Arjang Ruhparwar; Aviv Shaul; Laurens F Tops; Stephan Winnik; Tiny Jaarsma; Finn Gustafsson; Tuvia Ben Gal Journal: ESC Heart Fail Date: 2021-09-14
Authors: Jonathan B Edelson; Jonathan J Edwards; Hannah Katcoff; Antara Mondal; Feiyan Chen; Nosheen Reza; Thomas C Hanff; Heather Griffis; Jeremy A Mazurek; Joyce Wald; Danielle S Burstein; Pavan Atluri; Matthew J O'Connor; Lee R Goldberg; Payman Zamani; Peter W Groeneveld; Joseph W Rossano; Kimberly Y Lin; Edo Y Birati Journal: J Am Heart Assoc Date: 2022-01-13 Impact factor: 6.106